EXAMS · SÃO PAULO
Anti-RNA polymerase antibodies: cost, procedure and uses
A blood test that helps your doctor assess scleroderma and plan follow-up care.

Understand the exam
RNA polymerase is an enzyme, and it has three classes: I, II and III. In systemic sclerosis, the body may produce antibodies against them.
Anti-RNA polymerase antibodies are among the antibodies linked to systemic sclerosis. In one study, people with these antibodies had more kidney involvement: 29%, compared with 11% in the remaining patients. The result therefore helps plan follow-up.
At the clinic, the available version is called Anti-RNA polymerase I antibodies. The 2013 classification criteria for systemic sclerosis (ACR/EULAR) use the antibody against RNA polymerase III, so check with your doctor whether version I is appropriate for your case.
How it is done
The test involves drawing blood from a vein in the arm with a thin needle. A small amount of blood goes into a tube and is sent for analysis.
The result goes to the doctor who ordered the test, who explains what it means together with your history, physical examination and other antibodies.
When it is recommended
- Testing for antibodies against RNA polymerase I in the medical evaluation of systemic sclerosis (scleroderma) or overlap syndrome with systemic sclerosis, conditions with an established clinical association with this antibody. Check your doctor's order to confirm that the requested subtype is I, since the 2013 classification criteria for systemic sclerosis (ACR/EULAR) use the antibody against RNA polymerase III.
Does the exam hurt?
Cost and health plans
| Exam | Self-pay | Duration | Health plans |
|---|---|---|---|
| Anti-RNA polymerase I antibodies | From R$ 604.80 (≈ US$ 106, estimated) | Confirm with the team | Ask the team about coverage |
The team confirms the requested option, coverage, and conditions before booking.
Book an examFrequently asked questions
What does a positive anti-RNA polymerase result mean?
In people with systemic sclerosis, one study found more kidney involvement in those with anti-RNA polymerase antibodies. The doctor always makes the diagnosis, based on symptoms and other tests.
Does a negative result rule out scleroderma?
No, because no single test confirms or rules out systemic sclerosis. There are other antibodies associated with the disease, such as anticentromere antibodies and anti-Scl-70 (also called anti-topoisomerase I). These specific markers are usually mutually exclusive, meaning they rarely appear together in the same person.
What is the difference between anti-RNA polymerase and anti-Scl-70?
Anti-Scl-70 (anti-topoisomerase I) and anti-RNA polymerase antibodies target different enzymes, and each specific marker of systemic sclerosis is associated with a distinct pattern of skin involvement and other signs of the disease. In addition, while antibodies against RNA polymerase I or III are mainly associated with systemic sclerosis, anti-RNA polymerase II is not specific to this disease.
Is fasting required?
The team explains preparation and visit duration when you schedule.
How long do results take?
The team explains the turnaround time when assisting you.
Does my health plan cover the anti-RNA polymerase test?
Check the table on this page for plans with coverage on record. If your health plan is not listed, the team will confirm coverage for you.
What is the price of the test?
The self-pay price of the test is in the pricing table on this page.
Related exams
Where we see patients
References
- Harvey GR, et al. Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis. Clin Exp Immunol. 1999.
- Lazzaroni MG, Airò P. Anti-RNA polymerase III antibodies in patients with suspected and definite systemic sclerosis: Why and how to screen. J Scleroderma Relat Disord. 2018.
- van den Hoogen F, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2013.
- Elhannani A, et al. Anti-RNA polymerase III antibodies in systemic sclerosis: prevalence and clinical associations from a systematic review and meta-analysis. Rheumatology (Oxford). 2025.
- Satoh M, et al. Autoantibodies to RNA polymerase II are common in systemic lupus erythematosus and overlap syndrome. J Clin Invest. 1994.
- National Library of Medicine (MedlinePlus). What You Need to Know About Blood Testing. 2024.
- Satoh M, et al. Clinical Significance of Antinucleolar Antibodies: Biomarkers for Autoimmune Diseases, Malignancies, and others. Clin Rev Allergy Immunol. 2022.
This content is informational and does not replace a consultation.
Updated on